Clinical characteristics of programmed death-1 inhibitors for older patients with advanced pancreatic cancer

Table 1 Clinical characteristics of patients (n = 99), n (%)

Characteristic	Patients
Median age, years (range)	71.0 (65-84)
Age, years
< 75	70 (70.7)
≥ 75	29 (29.3)
Sex
Male	60 (60.6)
Female	39 (39.4)
ECOG PS
0-1	65 (65.7)
2	34 (34.3)
HBV infection
Positive	9 (9.1)
Negative	90 (90.9)
Primary pancreatic cancer
Head	46 (46.5)
Other	53 (53.5)
Number of lines of prior systemic therapy
0	70 (70.7)
1	29 (29.3)
Baseline serum CA199 levels (U/mL)
< 173.55	43 (43.4)
≥ 173.55	56 (56.6)
SII
< 531.575	49 (49.5)
≥ 531.575	50 (50.5)
NLR
< 2.1	38 (38.4)
≥ 2.1	61 (61.6)
PLR
< 217.91	74 (74.7)
≥ 217.91	25 (25.3)
PNI
< 45.6	54 (54.5)
≥ 45.6	45 (45.5)
HDL (mmol/L)
< 1.135	55 (55.6)
≥ 1.135	44 (44.4)
LDL (mmol/L)
< 2.26	52 (52.5)
≥ 2.26	47 (47.5)
TC (mmol/L)
< 4.045	56 (56.6)
≥ 4.045	43 (43.4)
TG (mmol/L)
< 1.315	55 (55.6)
≥ 1.315	44 (44.4)
With radiotherapy
Yes	24 (24.2)
No	75 (75.8)
With chemotherapy
Yes	79 (79.8)
No	20 (20.2)

ECOG PS: Eastern Cooperative Oncology Group performance status; HBV: Hepatitis B virus; CA199: Carbohydrate antigen 199; SII: Systemic immune-inflammation; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic nutritional index; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TC: Total cholesterol; TG: Triglyceride.